---
figid: PMC7393681__nihms-1590529-f0002
figlink: pmc/articles/PMC7393681/figure/F2/
number: Figure 2
caption: Insight into additional aspects of RAS protein and pathway regulation reveal
  more ways to potentially target RAS. Biancucci et al. showed that endopeptidase
  RRSP modification of RAS (I) impairs its interaction with downstream kinase RAF.
  Looking further downstream still, Blake et al. applied a MYC degradation screen
  to identify the kinase CDK9 as a positive regulator of MYC protein stability (II)
  and, consequently, cell growth and survival. Some clinically approved therapeutics
  indicated for targeting RAS activation and signaling in cancer are noted (red).
pmcid: PMC7393681
papertitle: 'RAS, wanted dead or alive: Advances in targeting RAS-mutant cancers.'
reftext: Clint A Stalnecker, et al. Sci Signal. ;13(624):eaay6013.
pmc_ranked_result_index: '16362'
pathway_score: 0.9591116
filename: nihms-1590529-f0002.jpg
figtitle: More RAS vulnerabilities, downstream
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7393681__nihms-1590529-f0002.html
  '@type': Dataset
  description: Insight into additional aspects of RAS protein and pathway regulation
    reveal more ways to potentially target RAS. Biancucci et al. showed that endopeptidase
    RRSP modification of RAS (I) impairs its interaction with downstream kinase RAF.
    Looking further downstream still, Blake et al. applied a MYC degradation screen
    to identify the kinase CDK9 as a positive regulator of MYC protein stability (II)
    and, consequently, cell growth and survival. Some clinically approved therapeutics
    indicated for targeting RAS activation and signaling in cancer are noted (red).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HRAS
  - KRAS
  - NRAS
  - ARAF
  - BRAF
  - RAF1
  - MAP2K1
  - MAP2K2
  - AKT2
  - AKT3
  - AKT1
  - MTOR
  - MAPK3
  - MAPK1
  - MYC
  - CDK9
  - Encorafenib
  - Dabrafenib
  - Vemurafenib
  - Binimetinib
  - Cobimetinib
  - Trametinib
  - Everolimus
  - H Sirolimus
  - Temsirolimus
  - DOO OO OO
  - Ser
genes:
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MYC
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: CDK9
  symbol: CDK9
  source: hgnc_symbol
  hgnc_symbol: CDK9
  entrez: '1025'
chemicals:
- word: Encorafenib
  source: ''
  identifier: ''
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Binimetinib
  source: MESH
  identifier: C581313
- word: Cobimetinib
  source: MESH
  identifier: C574276
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Everolimus
  source: MESH
  identifier: C107135
- word: H Sirolimus
  source: MESH
  identifier: D020123
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: DOO OO OO
  source: MESH
  identifier: C005863
- word: Ser
  source: MESH
  identifier: C530429
diseases: []
---
